Although several hypotheses have been proposed regarding the pathogenesis of PNSs, the precise mechanism that leads to the development of PNS remains largely unknown. (In simple terms, pathogenesis means “the manner of development of a disease”
Disclaimer. I read widely and noted various papers where there was clearly confusion about the classification of paraneoplastic in relation to Neuroendocrine Neoplasms. Some papers grouped known Neuroendocrine Tumour hormonal syndromes in, but others were more specific by filtering these into ectopic scenarios. This is a hugely complex area. I eventually filtered out papers based on the expertise of the authors and the common threads running in each one. It was not easy.
What are Paraneoplastic Syndromes (PNS)?
The term paraneoplastic syndrome (PNS) is used to define a spectrum of symptoms attributed to the production of biologically active substances secreted from tumors not related to their specific organ or tissue of origin and/or production of autoantibodies against tumor cells. (i.e. they are paraneoplastic in an ‘ectopic’ sense). Worth noting these are not the same as the known hormonal syndromes related to Neuroendocrine Tumours (NETs) but you will see some overlap within the paper used as a reference for most of this research. You will also note that the original name of the 2010 paper below was entitled Paraneoplastic Endocrine Syndromes. The word endocrine was removed in the 2020 update.
Important to note:
Although several hypotheses have been proposed regarding the pathogenesis of PNSs, the precise mechanism that leads to the development of PNS remains largely unknown. PNSs can precede, occur concomitantly or present at a later stage of tumor development and may complicate the patient’s clinical course, response to treatment, and impact overall prognosis. Their detection can facilitate the diagnosis of the underlying neoplasia, monitor response to treatment, detect early recurrences, and correlate with prognosis. When associated with tumors of low malignant potential PNSs usually do not affect long-term outcome. Conversely, in cases of highly malignant tumors, endocrine PNSs can be associated with poorer survival outcomes.
Clinical awareness and the incorporation into clinical practice of somatostatin receptor based PET scans such as the 68Ga Dotaxxx series, and other evolving biomarkers have substantially contributed to the identification of patients harbouring such syndromes.
Incidence
It has been estimated that PNSs affect approximately 8-15% of patients suffering from malignant neoplasms, mostly involving the lung, breast, and gastrointestinal system (not just NENs). Clearly a problem bigger than NENs. However, NENs are the type of tumours expected to exhibit the highest prevalence of PNSs due to their inherent synthetic and secretory capacity. However, to date the prevalence of NEN-related PNSs is still obscure due the limited availability of data.
According to the clinical manifestations, the NENs-related PNSs may be classified as:
I first wrote this blog using a paper published in 2010 (the source of the lead diagram and I include it for this purpose below). This was something I found in my research into the term Paraneoplastic Syndromes which has outlined some of these issues in relation to NENs. In the 2010 version, the authors suggested that paraneoplastic endocrine syndromes are a secondary complication with certain types and certain hormones. Many of these connections are already known, such as Cushing’s syndrome, hypercalcemia, hypoglycaemia. But it can be the knock-on effects of these conditions which can potentially lead to other issues discussed.
A further variation of the same paper was produced in 2020 contained updated information and Dr Ashley Grossman was again included in the authors list – he is a known expert in NENs and is an Endocrinologist. I noted the title changed from ‘secondary’ to ‘related’ indicating that thinking may have changed in 10 years. The other difference I noted was the omission of Endocrine leaving just Paraneoplastic Syndromes as a standalone statement.
There are many sites talking about Paraneoplastic Syndromes, but most seem to focus on the Neurological PNS sub-classification which is less relevant to NENs. I did note the National Insitute for Health (NIH) appeared to totally omit the endocrine aspects (humoral) instead focusing on the Neurological PSNs listed above. Consequently, they omit any connection to NEN Syndromes. Many other large and well-known US clinics take the same approach.
The one I will refer to below is more ‘endocrine’ related covering a much wider scope. It’s also authored by known NET Specialists who are Endocrinologists.
1. Paraneoplastic Syndromes Related to Neuroendocrine Tumors (2020)
Marina Tsoli, MD, PhD, Georgios K. Dimitriadis, Ioannis I. Androulakis, Gregory Kaltsas, M.D., FRCP, and Ashley Grossman, MD, FRCP, FMedSci. Paraneoplastic Syndromes Related to Neuroendocrine Tumors. [Updated 2020 Sep 26]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279135/
2. Paraneoplastic syndromes secondary to neuroendocrine tumours (2010)
Kaltsas G, Androulakis II, de Herder WW, Grossman AB. Paraneoplastic syndromes secondary to neuroendocrine tumours. Endocr Relat Cancer. 2010 Jul 28;17(3):R173-93. doi: 10.1677/ERC-10-0024. PMID: 20530594. https://pubmed.ncbi.nlm.nih.gov/20530594/
The 2020 paper is essentially an update of the 2010 original used as a reference to publish this blog.
I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me.
Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional. Some content may be generated by AI which can sometimes be misinterpreted. Please check any references attached.
Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.
Thanks for reading.
Blog Facebook. Like this page please.
Personal Facebook. Like this page please.
Awareness Facebook Like this page please.
Follow me on X (formerly twitter)
Check out my online presentations
Check out my WEGO Health Awards
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumours and Other Somatostatin Receptor 2-Expressing Tumours Read the
Here is the monthly summary of December 2025 on RonnyAllan.NET – Every share helps someone understand or even work towards a diagnosis, discovery of the
Summary of 2025 from Ronny It was a good year for my advocacy work but a difficult year personally which had some impact on my
15 Christmas celebrations since diagnosis. A thankful statement My Facebook memories today are full of Christmas activities including my first Christmas following diagnosis of advanced
A Global first for NET. Omni 128cm Total Body PET at the Peter MacCallum Cancer Centre in Melbourne Australia. According to Professor Michael Hofman, they
My diagnosis came with many strange words including, “carcinoid” and “neuroendocrine” ……… can you spell that please, I said to the doctor. I had a
Ronny Allan’s ‘PoNETry’ © series can be shared with poetry credit to: RonnyAllan.NET Thanks for reading Ronny I also have one about Lanreotide (or “butt
When I was diagnosed, I didn’t even feel ill. It was therefore a bit of a shock being told I had metastatic cancer, advanced enough to
I was assessing performance of the awareness period in November 2025 on Facebook and was astonished to find the size of my reach on that
I would also mention those who contributed to my “Tea Fund” which resides on PayPal. You don’t need a PayPal account as you can select a card but don’t forget to select the number of units first (i.e. 1 = £4, 2 = £8, 3 = £12, and so on), plus further on, tick a button to NOT create a PayPal account if you don’t need one. Clearly, if you have a PayPal account, the process is much simpler
Through your generosity, I am able to keep my sites running and provide various services for you. I have some ideas for 2023 but they are not detailed enough to make announcements yet.
This screenshot is from every single post on my website and depending on which machine you are using, it will either be top right of the post or at the bottom (my posts are often long, so scroll down!)
Subscribe to get the latest posts sent to your email.
